Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study has been completed.
Ambit Biosciences Corporation
Information provided by (Responsible Party):
Daiichi Sankyo Inc. Identifier:
First received: March 27, 2012
Last updated: November 11, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)